25 окт. 2024 г. · Our R&D pipeline includes 78 clinical-stage projects, 32 of which are in phase 3 or have been submitted to regulatory authorities for approval.

7 дек. 2023 г. · Sanofi shares insights into the development status and target indications of its pipeline of 12 potential blockbuster assets in immunology and ...

The Sanofi Specialty Care pipeline includes new molecular entities as well as potential new indications for existing products.

30 мая 2024 г. · “Immunoscience” is our way of looking at the role the immune system plays not only in how diseases work, but also how we can treat them.

A presentation providing a brief general overview of Sanofi's specialty care R&D pipeline, including investigational agents and proposed mechanistic targets in ...

6 дек. 2023 г. · Sanofi shares insights into the development status and target indications of its pipeline of 12 potential blockbuster assets in immunology and ...

25 окт. 2024 г. · All changes at CER and for Q3 2024 unless stated otherwise. 1. ALTUVIIIO, Nexviazyme, Rezurock, Sarclisa, Cablivi, Xenpozyme, Enjaymo, Tzield.

5 апр. 2024 г. · Sanofi is laying off staff around the globe following a 'full pipeline reprioritization,' according to an email from R&D chief Houman ...

Explore Sanofi's pioneering Immunology R&D and pipeline, focusing on immunoscience and precision medicine to tackle chronic systemic diseases.

ENACT is the first tissue-agnostic pipeline that integrates advanced cell segmentation with Visium HD transcriptomics data to infer cell types across whole ...